|Awarded On||February 19, 2020|
|Title||Role ofCMPK2 in Liver Inflammation and Hepatocellular Carcinoma|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Shuang Liang|
|Cancer Sites||Gallbladder, Liver and Intrahepatic Bile Duct|
Hepatocellular carcinoma (HCC)—the dominant form of liver cancer with no effective treatment strategies—has become the second leading cause of cancer-related death worldwide. Interestingly, almost all types of HCCs arise in the context of inflammation that is characterized by infiltration of immune cells to the liver where they produce inflammatory mediators to induce fibrosis/cirrhosis and eventually give rise to HCC. Therefore, understanding how inflammation is activated in the liver becomes important for developing effective anti-HCC therapies. Thanks to the close collaboration between clinical oncologists and bench scientists, we now know that activation of an immune sensor—called the NL...